A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.
The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Final Accrual
60
Trial Chairperson
Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
Related Post
15 July, 2025
New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial
TRIAL UPDATE: 15 July 2025 The TROG 20.01 CHEST-RT
8 July, 2025
Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial
TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE
